FY2027 EPS Estimates for Genmab A/S Lowered by William Blair

Genmab A/S (NASDAQ:GMAB - Free Report) - William Blair lowered their FY2027 earnings per share (EPS) estimates for Genmab A/S in a research note issued on Friday, May 9th. William Blair analyst M. Phipps now anticipates that the company will earn $2.58 per share for the year, down from their prior forecast of $2.69. William Blair has a "Outperform" rating on the stock. The consensus estimate for Genmab A/S's current full-year earnings is $1.45 per share.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, topping analysts' consensus estimates of $0.26 by $0.05. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%.

GMAB has been the subject of several other research reports. Leerink Partners upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price objective for the company in a research note on Thursday, February 13th. BNP Paribas raised Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 11th. Leerink Partnrs raised Genmab A/S from a "hold" rating to a "strong-buy" rating in a research report on Thursday, February 13th. Sanford C. Bernstein lowered Genmab A/S from a "market perform" rating to an "underperform" rating in a research report on Tuesday, April 1st. Finally, HC Wainwright reiterated a "buy" rating and issued a $37.00 price target (down from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. One analyst has rated the stock with a sell rating, three have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $39.17.

Genmab A/S Stock Performance

GMAB stock opened at $19.39 on Monday. Genmab A/S has a one year low of $17.24 and a one year high of $30.41. The firm has a market cap of $12.43 billion, a price-to-earnings ratio of 11.14, a PEG ratio of 2.65 and a beta of 1.04. The firm has a 50-day simple moving average of $20.07 and a two-hundred day simple moving average of $20.86.

Institutional Investors Weigh In On Genmab A/S

A number of institutional investors and hedge funds have recently modified their holdings of GMAB. EverSource Wealth Advisors LLC increased its holdings in Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock worth $26,000 after buying an additional 939 shares during the period. Headlands Technologies LLC boosted its holdings in shares of Genmab A/S by 1,525.0% in the 1st quarter. Headlands Technologies LLC now owns 1,560 shares of the company's stock valued at $31,000 after acquiring an additional 1,464 shares during the last quarter. Lindbrook Capital LLC increased its stake in shares of Genmab A/S by 105.4% in the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock worth $39,000 after acquiring an additional 950 shares during the period. GAMMA Investing LLC increased its stake in shares of Genmab A/S by 96.6% in the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock worth $45,000 after acquiring an additional 1,051 shares during the period. Finally, Barclays PLC raised its holdings in shares of Genmab A/S by 1,072.8% during the fourth quarter. Barclays PLC now owns 2,498 shares of the company's stock worth $52,000 after purchasing an additional 2,285 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company's stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.